{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:30Z","timestamp":1794097530948,"version":"4.8.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic immune-mediated diseases often associated with obesity, metabolic syndrome, and type 2 diabetes mellitus. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for T2DM, exert both metabolic and anti-inflammatory effects, which may offer therapeutic benefits for psoriatic disease, particularly in the early stages of PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This review aims to evaluate the current evidence on GLP-1RAs in PsO and PsA, examine the underlying pathophysiological mechanisms, and highlight key areas for future research, with a particular emphasis on early PsA as a critical window for intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review in accordance with current methodological guidance was conducted on published studies concerning GLP-1RAs in PsO and PsA, including preclinical, clinical, and mechanistic research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Several studies show that GLP-1RAs, particularly liraglutide and semaglutide, improve PsO severity, metabolic parameters, and inflammatory markers. These benefits extend beyond weight loss, suggesting a direct immunomodulatory effect. Two open-label trials in PsA patients with obesity indicated improvements in disease activity (MDA) alongside metabolic benefits. The trials, NCT06588296 (TOGETHER-PsA) and NCT06864026 (TOGETHER AMPLIFY-PsA), assessed ixekizumab with and without tirzepatide. However, evidence in PsA remains limited, with most studies constrained by small sample sizes and short follow-up periods. To date, no studies have specifically investigated GLP-1RAs in early PsA; however, early-stage disease may represent an optimal treatment window for maximizing therapeutic effects based on immunometabolic rationale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1RAs show promising effects in PsO and early-PsA may represent a potential treatment window for maximizing therapeutic effects based on immunometabolic rationale, although this concept requires validation in dedicated clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1744308","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:39:26Z","timestamp":1777354766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities"],"prefix":"10.3389","volume":"17","author":[{"given":"Giovanni","family":"Ciancio","sequence":"first","affiliation":[{"name":"Chair of Rheumatology, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Maranini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara","place":["Ferrara, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria Sant\u2019Anna di Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Sandri","sequence":"additional","affiliation":[{"name":"Chair of Rheumatology, University of Modena and Reggio Emilia","place":["Modena, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Amati","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara","place":["Ferrara, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria Sant\u2019Anna di Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Silvagni","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara","place":["Ferrara, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria Sant\u2019Anna di Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara","place":["Ferrara, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliera Universitaria Sant\u2019Anna di Ferrara","place":["Ferrara, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilia","family":"Giuggioli","sequence":"additional","affiliation":[{"name":"Chair of Rheumatology, University of Modena and Reggio Emilia","place":["Modena, Italy"]},{"name":"Rheumatology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649408","article-title":"Cutaneous and systemic psoriasis: Classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19683","DOI":"10.1038\/s41598-024-70707-w","article-title":"Cardiovascular comorbidities among patients with psoriasis: A national register-based study in China","volume":"14","author":"Cui","year":"2024","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12902-025-01996-z","article-title":"Diabetes is associated with a poor prognosis in patients with psoriasis and coronary artery disease","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12388","article-title":"Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis","volume":"278","author":"Gyldenl\u00f8ve","year":"2015","journal-title":"J\u00a0Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07637-z","article-title":"Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: A meta-analysis","volume":"44","author":"Andreasson","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.997578","article-title":"Glp-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity-inflammation axis in psoriatic disease: Mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (Grappa): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224148","article-title":"Eular points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004314","article-title":"Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage","volume":"10","author":"Zabotti","year":"2024","journal-title":"RMD Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031740","article-title":"Immunopathology of psoriasis and psoriatic arthritis","author":"Veale","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The Il-17 family in diseases: From bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","article-title":"Skin expression of Il-23 drives the development of psoriasis and psoriatic arthritis in mice","volume":"10","author":"Chen","year":"2020","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: Tnf-\u03b1, Il-23\/Il-17a, and Jak-dependent inflammation in the pathogenesis of psoriatic synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(23)00124-8","article-title":"Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors\u2019 reply","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: From pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: A narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41598-017-02660-w","article-title":"Immune cell-derived cytokines contribute to obesity-related inflammation, fibrogenesis and metabolic deregulation in human adipose tissue","volume":"7","author":"Ca\u00ebr","year":"2017","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00022","article-title":"Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease","volume":"7","author":"Chait","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000012","article-title":"Obesity and inflammatory arthritis: Impact on occurrence, disease characteristics and therapeutic response","volume":"1","author":"Da\u00efen","year":"2015","journal-title":"RMD Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x241271886","article-title":"Metabolic syndrome and psoriatic arthritis: The role of weight loss as a disease-modifying therapy","volume":"16","author":"Williams","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00380-3","article-title":"Deciphering the association between psoriasis and obesity: Current evidence and treatment considerations","volume":"9","author":"Paroutoglou","year":"2020","journal-title":"Curr Obes Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: A prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140021","article-title":"High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease","volume":"41","author":"Haroon","year":"2014","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672519","article-title":"Insulin signaling in arthritis","volume":"12","author":"Tripolino","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.735150","article-title":"Psoriatic arthritis and metabolic syndrome: Is there a role for disease modifying anti-rheumatic drugs","volume":"8","author":"Atzeni","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2025.105904","article-title":"Weighing in on obesity and psoriatic arthritis - time to move beyond association to robust randomised trials","volume":"92","author":"Siebert","year":"2025","journal-title":"Joint Bone Spine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105647","article-title":"Weight loss affects disease activity and treatment response in inflammatory rheumatic diseases","volume":"91","author":"Tournadre","year":"2024","journal-title":"Joint Bone Spine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of Glp-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01302-0","article-title":"Glucagon-like peptide-1 receptor agonists in arthritis: Current insights and future directions","volume":"21","author":"Karacabeyli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13051128","article-title":"Glp-1r agonists and their therapeutic potential in inflammatory bowel disease and other immune-mediated inflammatory diseases, a systematic review of the literature","volume":"13","author":"Thin","year":"2025","journal-title":"Biomedicines"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1999-3","article-title":"Writing a narrative biomedical review: Considerations for authors, peer reviewers, and editors","volume":"31","author":"Gasparyan","year":"2011","journal-title":"Rheumatol Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (Glp-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan","year":"2011","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Al-Badri","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1882658","article-title":"Efficacy of Glp-1ra, liraglutide, in plaque psoriasis treatment with type 2 diabetes: A systematic review and meta-analysis of prospective cohort and before-after studies","volume":"33","author":"Chang","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/metabo13040493","article-title":"Effects of hypolipidemic drugs on psoriasis","volume":"13","author":"Matwiejuk","year":"2023","journal-title":"Metabolites"},{"key":"B45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: An open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107","year":"2025","journal-title":"Biomolecules"},{"key":"B46","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41573-025-01231-3","article-title":"Author correction: Glp-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2297-z","article-title":"Glucagon-like peptide-1 (Glp-1) receptor agonists, obesity and psoriasis: Diabetes meets dermatology","volume":"54","author":"Drucker","year":"2011","journal-title":"Diabetologia"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.immuni.2023.06.021","article-title":"Obesity-induced dysregulation of skin-resident Ppar\u03b3(+) Treg cells promotes Il-17a-mediated psoriatic inflammation","volume":"56","author":"Sivasami","year":"2023","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"Glp-1 receptor agonist impairs keratinocytes inflammatory signals by activating ampk","volume":"107","author":"Yang","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12380","article-title":"Liraglutide in combination with acitretin for severe recalcitrant psoriasis","volume":"169","author":"Reid","year":"2013","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106941","article-title":"Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control","volume":"164","author":"Nicolau","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1708853","article-title":"Liraglutide improved inflammation via mediating il-23\/th-17 pathway in obese diabetic mice with psoriasiform skin","volume":"32","author":"Chen","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/edm-21-0007","article-title":"Two birds one stone: Semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1530\/edm-23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.022","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with psoriasis is associated with lower incidence of atherosclerotic cardiovascular disease: a retrospective cohort study using trinetx","volume":"93","author":"Sontam","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2025.501809","article-title":"Effects of liraglutide among patients with psoriatic arthritis and obesity","volume":"21","author":"Nicolau","year":"2025","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104473","article-title":"Biological and synthetic target dmards in psoriatic arthritis","volume":"149","author":"Silvagni","year":"2019","journal-title":"Pharmacol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic dmards in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. a systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-023-03105-8","article-title":"Serum il-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention","volume":"25","author":"Landgren","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2022-eular.40","article-title":"Pos1013 how does body mass index affect secukinumab treatment outcomes and safety in patients with psoriatic arthritis? \u2013 real world data from the german aquila study","volume":"81","author":"Kiltz","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217251","article-title":"Secukinumab efficacy in patients with psa is not dependent on patients\u2019 body mass index","volume":"81","author":"Pantano","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss\u00a0improves the response of obese patients with moderate-to-severe chronic plaque\u00a0psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3390\/ijms25052475","article-title":"The effect of a ketogenic diet versus mediterranean diet on clinical and biochemical markers of inflammation in patients with obesity and psoriatic arthritis: a randomized crossover trial","volume":"25","author":"Lambadiari","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.792846","article-title":"The effect of ketogenic diet on inflammatory arthritis and cardiovascular health in rheumatic conditions: a mini review","volume":"8","author":"Ciaffi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70103","article-title":"Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis","volume":"7","author":"Kellner","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf346","article-title":"Glp-1ra and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study","volume":"194","author":"Olbrich","year":"2025","journal-title":"Br J Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/2pmt67","article-title":"From pain catastrophising to multidimensional psychological distress: unravelling the complexity of difficult-to-treat psoriatic arthritis","volume":"43","author":"Currado","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12916-022-02672-y","article-title":"Obese visceral fat tissue inflammation: from protective to detrimental","volume":"20","author":"Kolb","year":"2022","journal-title":"BMC Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1530067","article-title":"Association between metabolic score for insulin resistance and lower limb pain among the elderly: a cross-sectional study","volume":"16","author":"Hu","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae547","article-title":"A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients","volume":"64","author":"Carlucci","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103864","article-title":"Glucagon-like peptide-1 (glp-1) receptor agonists in rheumatology: a review of current evidence and future directions","volume":"24","author":"Bilgin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B78","volume-title":"NCT06475586. Effect of Semaglutide on the Psoriatic Lesions in Patients with Type 2 Diabetes Mellitus","year":""},{"key":"B79","volume-title":"NCT06937060. Effect of Semaglutide in Patients with Psoriasis and Obesity (Sempso)","year":""},{"key":"B80","volume-title":"NCT06588296. Ixekizumab Concomitantly Administered with Tirzepatide in Adults with Psoriatic Arthritis and Obesity or Overweight (Together-Psa)","author":"Merola","year":""},{"key":"B81","volume-title":"NCT06864026. A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants with Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (Together Amplify-Psa)","year":""},{"key":"B82","volume-title":"NCT02472717. Psoriatic Arthritis Treated with Liraglutide Therapy: A Quality of Life and Efficacy Study (Plaque)","year":""},{"key":"B83","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"Eular recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheumatic Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:39:29Z","timestamp":1777354769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1744308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2026.1744308"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1744308","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1744308"}}